MA47165B1 - Inhibiteurs de la poly-adp-ribose polymérase (parp) - Google Patents
Inhibiteurs de la poly-adp-ribose polymérase (parp)Info
- Publication number
- MA47165B1 MA47165B1 MA47165A MA47165A MA47165B1 MA 47165 B1 MA47165 B1 MA 47165B1 MA 47165 A MA47165 A MA 47165A MA 47165 A MA47165 A MA 47165A MA 47165 B1 MA47165 B1 MA 47165B1
- Authority
- MA
- Morocco
- Prior art keywords
- parp
- adp
- poly
- inhibitors
- ribose polymerase
- Prior art date
Links
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 title abstract 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title abstract 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440581P | 2016-12-30 | 2016-12-30 | |
| PCT/US2017/068636 WO2018125961A1 (en) | 2016-12-30 | 2017-12-28 | Poly-adp ribose polymerase (parp) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA47165A MA47165A (fr) | 2019-11-06 |
| MA47165B1 true MA47165B1 (fr) | 2021-06-30 |
Family
ID=61007849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA47165A MA47165B1 (fr) | 2016-12-30 | 2017-12-28 | Inhibiteurs de la poly-adp-ribose polymérase (parp) |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11034670B2 (https=) |
| EP (1) | EP3562822B1 (https=) |
| JP (1) | JP7141399B2 (https=) |
| KR (1) | KR102606799B1 (https=) |
| CN (1) | CN110167926B (https=) |
| AR (1) | AR110706A1 (https=) |
| AU (1) | AU2017388376B2 (https=) |
| CA (1) | CA3047137A1 (https=) |
| CO (1) | CO2019007906A2 (https=) |
| CY (1) | CY1124565T1 (https=) |
| DK (1) | DK3562822T3 (https=) |
| EA (1) | EA201991412A1 (https=) |
| ES (1) | ES2875841T3 (https=) |
| HR (1) | HRP20210887T1 (https=) |
| HU (1) | HUE054382T2 (https=) |
| IL (1) | IL267676B (https=) |
| JO (1) | JOP20190115B1 (https=) |
| LT (1) | LT3562822T (https=) |
| MA (1) | MA47165B1 (https=) |
| MD (1) | MD3562822T2 (https=) |
| MX (1) | MX393606B (https=) |
| MY (1) | MY199045A (https=) |
| PH (1) | PH12019501529A1 (https=) |
| PL (1) | PL3562822T3 (https=) |
| PT (1) | PT3562822T (https=) |
| RS (1) | RS61895B1 (https=) |
| SA (1) | SA519401894B1 (https=) |
| SI (1) | SI3562822T1 (https=) |
| SM (1) | SMT202100321T1 (https=) |
| TW (1) | TWI773718B (https=) |
| UA (1) | UA124777C2 (https=) |
| WO (1) | WO2018125961A1 (https=) |
| ZA (2) | ZA201904004B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102667386B1 (ko) * | 2015-10-07 | 2024-05-21 | 미토브리지, 인크. | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 |
| MX393606B (es) * | 2016-12-30 | 2025-03-19 | Mitobridge Inc | Inhibidores de poli-adp ribosa polimerasa (parp) |
| US12459899B2 (en) | 2019-10-30 | 2025-11-04 | DIGMBIO, Inc. | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient |
| CA3213029A1 (en) * | 2021-04-22 | 2022-10-27 | Yuli Xie | Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof |
| CN118076585A (zh) * | 2021-07-23 | 2024-05-24 | 国家医疗保健研究所 | 革兰氏阴性菌外排泵抑制剂 |
| CN113603630B (zh) * | 2021-08-10 | 2023-06-27 | 苏州小栗医药科技有限公司 | 一种4-苯基哌啶盐酸盐的合成方法 |
| JP2025531246A (ja) | 2022-09-19 | 2025-09-19 | ビーエーエスエフ ソシエタス・ヨーロピア | アゾール系殺有害生物化合物 |
| AU2023377192A1 (en) | 2022-11-07 | 2025-05-22 | Kyoto University | Nitrogen-containing heterocyclic compound |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN120917007A (zh) * | 2023-05-19 | 2025-11-07 | 上海海和药物研究开发股份有限公司 | 一种芳基脲类parp1抑制剂、其制备方法及用途 |
| CN117024357B (zh) * | 2023-07-03 | 2026-02-24 | 山东第二医科大学 | 一种针对brca突变的选择性抑制剂及其用途 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| CN117510404A (zh) * | 2023-11-29 | 2024-02-06 | 山西永津集团有限公司 | 一种4-氨基烟酸的制备方法 |
| WO2025111705A1 (en) * | 2023-11-30 | 2025-06-05 | Waverley Pharma Inc. | Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN118084678B (zh) * | 2024-03-01 | 2024-09-06 | 长沙唯楚医药科技有限公司 | 一种2-溴-6-氟苯胺的制备方法 |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025227032A1 (en) * | 2024-04-26 | 2025-10-30 | Remix Therapeutics Inc. | Methods for degradation of cyclin k and inhibition of cyclin dependent kinases |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020082268A1 (en) | 2000-03-20 | 2002-06-27 | Yun Gao | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof |
| US20030087917A1 (en) | 2000-03-27 | 2003-05-08 | Dorothea Strack | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| WO2005082887A1 (ja) | 2004-02-26 | 2005-09-09 | Aska Pharmaceutical Co., Ltd. | ピリミジン誘導体 |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| MXPA06014933A (es) * | 2004-06-30 | 2007-02-28 | Janssen Pharmaceutica Nv | Derivados de 2-alquil quinazolinona sustituidos como inhibidores de poli(adp-ribosa) polimerasa-1. |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| WO2007011623A1 (en) | 2005-07-15 | 2007-01-25 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| EP2010505B1 (en) | 2006-03-28 | 2012-12-05 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| WO2012140642A1 (en) | 2011-04-10 | 2012-10-18 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| CN102838600A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
| WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| AU2014298955B2 (en) | 2013-07-31 | 2018-03-01 | Merck Patent Gmbh | Oxoquinazolinyl-butanamide derivatives |
| CA2948067A1 (en) | 2014-05-07 | 2015-11-12 | Merck Patent Gmbh | Heterocyclyl-butanamide derivatives |
| CN105924434A (zh) * | 2015-02-28 | 2016-09-07 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
| US11186564B2 (en) | 2016-08-04 | 2021-11-30 | Sunovion Pharmaceuticals Inc. | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders |
| MX393606B (es) * | 2016-12-30 | 2025-03-19 | Mitobridge Inc | Inhibidores de poli-adp ribosa polimerasa (parp) |
-
2017
- 2017-12-28 MX MX2019007870A patent/MX393606B/es unknown
- 2017-12-28 HR HRP20210887TT patent/HRP20210887T1/hr unknown
- 2017-12-28 HU HUE17832694A patent/HUE054382T2/hu unknown
- 2017-12-28 MA MA47165A patent/MA47165B1/fr unknown
- 2017-12-28 SI SI201730772T patent/SI3562822T1/sl unknown
- 2017-12-28 JP JP2019535356A patent/JP7141399B2/ja active Active
- 2017-12-28 KR KR1020197021891A patent/KR102606799B1/ko active Active
- 2017-12-28 MY MYPI2019003419A patent/MY199045A/en unknown
- 2017-12-28 EA EA201991412A patent/EA201991412A1/ru unknown
- 2017-12-28 EP EP17832694.8A patent/EP3562822B1/en active Active
- 2017-12-28 CA CA3047137A patent/CA3047137A1/en active Pending
- 2017-12-28 SM SM20210321T patent/SMT202100321T1/it unknown
- 2017-12-28 DK DK17832694.8T patent/DK3562822T3/da active
- 2017-12-28 PT PT178326948T patent/PT3562822T/pt unknown
- 2017-12-28 LT LTEP17832694.8T patent/LT3562822T/lt unknown
- 2017-12-28 MD MDE20191268T patent/MD3562822T2/ro unknown
- 2017-12-28 AU AU2017388376A patent/AU2017388376B2/en active Active
- 2017-12-28 PL PL17832694T patent/PL3562822T3/pl unknown
- 2017-12-28 ES ES17832694T patent/ES2875841T3/es active Active
- 2017-12-28 RS RS20210653A patent/RS61895B1/sr unknown
- 2017-12-28 WO PCT/US2017/068636 patent/WO2018125961A1/en not_active Ceased
- 2017-12-28 US US16/473,127 patent/US11034670B2/en active Active
- 2017-12-28 UA UAA201908940A patent/UA124777C2/uk unknown
- 2017-12-28 JO JOP/2019/0115A patent/JOP20190115B1/ar active
- 2017-12-28 CN CN201780082024.8A patent/CN110167926B/zh active Active
- 2017-12-29 AR ARP170103718A patent/AR110706A1/es active IP Right Grant
- 2017-12-29 TW TW106146555A patent/TWI773718B/zh active
-
2019
- 2019-05-29 SA SA519401894A patent/SA519401894B1/ar unknown
- 2019-06-20 ZA ZA2019/04004A patent/ZA201904004B/en unknown
- 2019-06-26 IL IL267676A patent/IL267676B/en unknown
- 2019-06-28 PH PH12019501529A patent/PH12019501529A1/en unknown
- 2019-07-23 CO CONC2019/0007906A patent/CO2019007906A2/es unknown
-
2020
- 2020-06-03 ZA ZA2020/03310A patent/ZA202003310B/en unknown
-
2021
- 2021-06-08 CY CY20211100500T patent/CY1124565T1/el unknown
- 2021-06-09 US US17/342,873 patent/US11993585B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47165B1 (fr) | Inhibiteurs de la poly-adp-ribose polymérase (parp) | |
| GEAP202416515A (en) | Quinoline compounds as inhibitors of kras | |
| MA57412B1 (fr) | Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés | |
| MA47217A (fr) | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique | |
| MA43131B1 (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
| MA44721B1 (fr) | Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA51431B1 (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MA32231B1 (fr) | Composés organiques | |
| MA53668B1 (fr) | Traitement de la drépanocytose avec un composé activant la pyruvate kinase r | |
| MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
| MA42811A (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| MA41238A (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
| MA54386B1 (fr) | Modulateurs de trex1 | |
| GEAP202215599A (en) | Boron containing pde4 inhibitors | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA39315A1 (fr) | Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique | |
| MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
| MA38250B1 (fr) | Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie | |
| MA39926B1 (fr) | Dérivés de dihétérocycle liés à cycloalkyle | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MA44383B1 (fr) | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer | |
| MA43507B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA45367B1 (fr) | Inhibiteurs de la tyrosine kinase |